Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
PHASE1CompletedINTERVENTIONAL
Enrollment
57
Participants
Timeline
Start Date
December 14, 2015
Primary Completion Date
June 27, 2019
Study Completion Date
November 8, 2019
Conditions
Solid Tumors
Interventions
DRUG
RC48-ADC
Trial Locations (1)
100142
Beijing Cancer Hospital, Beijing
All Listed Sponsors
lead
RemeGen Co., Ltd.
INDUSTRY
NCT02881190 - Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter